Physician profile
Aaroop Haridas
NPI 1871881284
$3,920.14
in general payments reported to CMS, 2019-2025
27 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.25 · 2022: $83.81 · 2023: $748 · 2024: $1,610 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,822.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,279.35 | 2022-2025 | |
| Amgen INC. | $570.24 | 2021-2025 | Tavneos, Otezla, Enbrel |
| Mallinckrodt Hospital Products INC. | $290.12 | 2023-2025 | Acthar |
| Pfizer INC. | $250.04 | 2023-2025 | |
| Glaxosmithkline, LLC. | $175.58 | 2023-2025 | Benlysta |
| Boston Scientific Corporation | $140.53 | 2023 | Wavewriter Alpha Prime 16 |
| Neurelis, INC. | $138.16 | 2023-2025 | Valtoco |
| Horizon Therapeutics Plc | $116.76 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.48 | 2023-2024 | Cyltezo, Ofev |
| Axsome Therapeutics, INC. | $91.69 | 2023-2025 | Sunosi |
| Lundbeck LLC | $88.92 | 2024-2025 | Vyepti |
| Ucb, INC. | $80.00 | 2023-2025 | Briviact, Rystiggo, Nayzilam |
| E.R. Squibb & Sons, L.L.C. | $77.20 | 2025 | Orencia |
| Janssen Biotech, INC. | $71.20 | 2023-2025 | Tremfya |
| Teva Pharmaceuticals USA, INC. | $65.49 | 2023-2025 | Ajovy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $64.89 | 2024-2025 | Crexont, Ongentys |
| Kedrion Biopharma, INC. | $58.22 | 2025 | Koate, Kedrab, Gammaked |
| Argenx US, INC. | $55.23 | 2024 | Vyvgart |
| Novartis Pharmaceuticals Corporation | $37.28 | 2023 | |
| Jazz Pharmaceuticals INC. | $30.60 | 2024 | |
| Harmony Biosciences LLC | $22.10 | 2023 | Wakix |
| Eisai INC. | $20.65 | 2024 | |
| Tanabe Pharma America, INC. | $20.46 | 2024 | |
| Kyowa Kirin, INC. | $17.60 | 2024 | Nourianz |
| Lilly USA, LLC | $16.52 | 2025 | Zepbound |
| Biogen, INC. | $15.58 | 2025 | Skyclarys |
| Nevro Corp. | $13.25 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaroop Haridas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.